Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice

European Journal of Pharmacology

Volumn 398, Issue 3, 2000, Pages 381-387

  Katoh, Makoto ^a   Ohmachi, Yasushi ^a   Kurosawa, Yukie ^a   Yoneda, Hikaru ^a   Tanaka, Norio ^a   Narita, Hiroshi ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Diabetes; Immunohistochemistry; Nephropathy; Urinary albumin excretion

Indexed keywords

CAPTOPRIL; IMIDAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVITY; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; STREPTOZOCIN DIABETES;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CAPTOPRIL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; IMIDAZOLES; IMIDAZOLIDINES; MALE; MICE; MICE, INBRED C57BL; PEPTIDYL-DIPEPTIDASE A; RENAL ARTERY; STREPTOZOCIN;

EID: 0034705836     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00320-4     Document Type: Article

References (31)

1. Anderson S., Rennke H.G., Garcia D.L., Brenner B.M. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 36:1989;526-536.
2. Anderson S., Jung F.F., Ingelfinger J.R. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am. J. Physiol. 265:1993;F477-F486.
3. Bjorck S., Mulec H., Johnsen S.A., Norden G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br. Med. J. 304:1992;339-343.
4. Bohlen L., de Courten M., Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am. J. Hypertens. 7:1994;84s-92s.
5. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J.P., Arveiler D., Luc G., Bard J.M., Bara L., Richard S., Tiret L., Amouyel P., Alhenc-Gelas F., Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644.
6. Cartwright M.E., Jaenke R.S. Effects of dietary protein and captopril on glomerular permselectivity in rats with unilateral nephrectomy. Lab. Invest. 59:1988;492-499.
7. Cheung H.S., Cushman D.W. Inhibition of homogenous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochim. Biophys. Acta. 293:1973;451-463.
8. Cushman D.W., Wang F.L., Fung W.C., Harvey C.M., DeForrest J.M. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypertens. 2:1989;294-306.
9. Drury P.L. Diabetes and arterial hypertension. Diabetologia. 4:1983;1-9.
10. Gansevoort R.T., Sluiter W.J., Hemmelder M.H., de Zeeuw D., de Jong P.E. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol., Dial., Transplant. 10:1995;1963-1974.
11. Gibbons G.H., Pratt R.E., Dzau V.J. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J. Clin. Invest. 90:1992;456-461.
12. Gilbert R.E., Cox A., Wu L.L., Allen T.J., Hulthen U.L., Jerums G., Cooper M.E. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes. 47:1998;414-422.
13. Gilbert R.E., Wu L.L., Kelly D.J., Cox A., Wilkinson-Berka J.L., Cooper M.E. Pathological expression of renin and angiotensin II in the renal tuble after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am. J. Pathol. 155:1999;429-440.
14. Johnson R.J., Alpers C.E., Yoshimura A., Lombardi D., Pritzl P., Floege J., Schwartz S.M. Renal injury from angiotensin II-mediated hypertension. Hypertension. 19:1992;464-474.
15. Kagami S., Border W.A., Miller D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 93:1994;2431-2437.
16. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329:1993;1456-1462.
17. Mathiesen E.R., Hommel E., Giese J., Parving H.H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br. Med. J. 303:1991;81-87.
18. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br. Med. J. 285:1982;685-688.
19. Mogensen C.E., Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patient. N. Engl. J. Med. 311:1984;89-93.
20. Morelli E., Loon N., Meyer T., Peters W., Myers B.D. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes. 39:1990;76-82.
21. Müller D.N., Bohlender J., Hilgers K.F., Dragun D., Costerousse O., Ménard J., Luft F.C. Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension. 29:1997;98-104.
22. Nakajima T., Yamada T., Setoguchi M. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 19:1992;102-107.
23. Nyström F., Karlberg B.E., Öhman K.P. Serum angiotensin-converting enzyme activity correlates positively with plasma angiotensin II: a population-based study of ambulatory blood pressure and the renin-angiotensin system. J. Hum. Hypertens. 11:1997;301-306.
24. Rasch R., Mogensen C.E. Urinary excretion of albumin and total protein in normal and streptozotocin diabetic rats. Acta Endocrinol. 95:1980;376-381.
25. Rodby R.A., Rohde R., Evans J., Bain R.P., Mulcahy W.S., Lewis E.J. The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics, Collaborative Study Group. J. Am. Soc. Nephrol. 5:1995;1775-1781.
26. Rumble J.R., Gilbert R.E., Cox A., Wu L., Cooper M.E. Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy. J. Hypertens. 16:1998;1603-1609.
27. Ruzicka M., Skarda V., Leenen F.H. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation. 92:1995;3568-3573.
28. Sassy-Prigent C., Heudes D., Jouquey S., Auberval D., Belair M.F., Michel O., Hamon G., Bariety J., Bruneval P. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition. Lab. Invest. 73:1995;64-71.
29. Sowers J.R., Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 26:1995;869-879.
30. Tikkanen T., Tikkanen I., Rockell M.D., Allen T.J., Johnston C.I., Cooper M.E., Burrell L.M. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension. 32:1998;778-785.
31. Yotsumoto T., Naitoh T., Shikada K., Tanaka S. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Jpn. J. Pharmacol. 75:1997;59-64.